Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Current Assets
Cash and cash equivalents	$ 72,135	$ 6,227
Prepaid expenses and other current assets	1,422	1,707
Total Current Assets	73,557	7,934
Property and equipment, net	115	174
Right of use asset	1,426	279
Deposits and other assets	23	23
Total Assets	75,121	8,410
Current Liabilities:
Accounts payable	1,255	886
Accrued expenses	1,009	925
Accrued employee benefits	721	868
Operating lease liability	175	287
Total Current Liabilities	3,160	2,966
Lease liability - long term	1,401	186
Total Liabilities	4,561	3,152
Commitments and Contingencies
Series A Preferred Stock, $0.001 par value; 10,000,000 shares authorized; 0 and 120,000 issued and outstanding as of September 30, 2021 and December 31, 2020, respectively	0	12,798
Stockholders' Equity (Deficit):
Series B Preferred Stock, $1,000 par value; 10,000,000 shares authorized, 0 issued and outstanding and 3,973 issued and outstanding as of September 30, 2021 and December 31, 2020, respectively	0	2,477
Common stock, $0.001 par value; 200,000,000 shares authorized, 132,044,866 issued and 132,042,538 outstanding at September 30, 2021 and 29,252,253 issued and 29,249,925 outstanding at December 31, 2020	132	29
Additional paid-in capital	339,223	240,821
Accumulated deficit	(266,021)	(248,094)
Total Synthetic Biologics, Inc. and Subsidiaries Equity (Deficit)	73,334	(4,767)
Non-controlling interest	(2,774)	(2,773)
Total Stockholders' Equity (Deficit)	70,560	(7,540)
Total Liabilities and Stockholders' Equity (Deficit)	$ 75,121	$ 8,410